Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 4/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | TET3 | O43151 | 1/20 | 0.33 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL2379633 | 0.92 | TET2 (0.31) | TET2 | |
| N,N-Dimethylethanaminium SCHEMBL444410 | 0.88 | TET2 (0.37) | TET2FFAR3TET3TET1GRIK1 | |
| Trimethylammonium SCHEMBL20907 | 0.87 | FFAR3 (0.40) | TET2FFAR3TET3TET1GRIK1 | |
| Trimethylammonium SCHEMBL1226064 | 0.85 | FFAR3 (0.38) | TET2FFAR3TET3TET1GRIK1 | |
| Trimethylammonium SCHEMBL9095442 | 0.85 | FFAR3 (0.38) | TET2FFAR3TET3TET1GRIK1 | |
| Trimethylammonium SCHEMBL141478 | 0.85 | FFAR3 (0.38) | TET2FFAR3TET3TET1GRIK1 | |
| Trimethylammonium SCHEMBL2478116 | 0.85 | FFAR3 (0.38) | TET2FFAR3TET3TET1GRIK1 | |
| Trimethylammonium SCHEMBL460229 | 0.85 | FFAR3 (0.38) | TET2FFAR3TET3TET1GRIK1 | |
| SCHEMBL865345 | 0.85 | — | — | |
| SCHEMBL17865 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6656507-B2 | Mixture of polymethacrylate and carboxymethyl cellulose | ROEHM GMBH & CO. KG (DE) | 2003-12-02 | — | — | US | claimed |
| US-20010055619-A1 | AQUEOUS DISPERSION SUITABLE FOR THE PRODUCTION OF COATINGS AND BINDERS FOR SOLID ORAL DRUGS | ROHM GMBH (DE) | 2001-12-27 | — | — | US | claimed |
| US-20260137690-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | AXSOME THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12616702-B2 | Use of reboxetine to treat narcolepsy | AXSOME THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260097040-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | AXSOME THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260041691-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | AXSOME THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260014165-A1 | USE OF ESREBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS SUCH AS FIBROMYALGIA | AXSOME THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260014142-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | AXSOME THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260014163-A1 | USE OF REBOXETINE TO TREAT FIBROMYALGIA | AXSOME THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250360107-A1 | USE OF MAZINDOL TO TREAT NERVOUS SYSTEM DISORDERS | AXSOME THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12447155-B2 | Use of reboxetine to treat narcolepsy | AXSOME THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20030198673-A1 | Controlled release formulations coated with aqueous dispersions of acrylic polymers | OSHLACK BENJAMIN (US) | 2003-10-23 | — | — | US | disclosed |
| WO-2003035791-A1 | COMPOSITION FOR AVOIDING OR REDUCING THE BUILD-UP OF ICE AND SNOW, METHOD FOR PRODUCTION AND USE OF SAID COMPOSITION | BASF AKTIENGESELLSCHAFT (DE) | 2003-05-01 | — | — | WO | disclosed |
| US-20010055619-A1 | AQUEOUS DISPERSION SUITABLE FOR THE PRODUCTION OF COATINGS AND BINDERS FOR SOLID ORAL DRUGS | ROHM GMBH (DE) | 2001-12-27 | — | — | US | disclosed |
| US-6143353-A | HYDROPHOBIC, STORAGE STABILITY, | PURDUE PHARMA LP (US) | 2000-11-07 | — | — | US | disclosed |
| EP-0955041-A2 | Aqueous dispersion useful for the production of coating and binding means for oral solid medicament | RÖHM GMBH (DE) | 1999-11-10 | — | — | EP | disclosed |
| US-5639476-A | STABILITY | EURO-CELTIQUE, S.A. (LU) | 1997-06-17 | — | — | US | disclosed |
| US-5580578-A | SUSTAIN RELEASED BEADS COATED WITH A COPOLYMERS OF ACRYLIC AND METHACRYLIC ESTERS HAVING QUATERNARY AMMONIUM GROUP; STORAGE STABILITY, WATERPROOFING | EURO-CELTIQUE, S.A. (LU) | 1996-12-03 | — | — | US | disclosed |
| EP-0636366-A2 | Controlled release formulations coated with aqueous dispersions of acrylic polymers | Euroceltique S.A. (LU) | 1995-02-01 | — | — | EP | disclosed |
| US-4737357-A | WATER INSOLUBLE, SWELLING QUATERNARY AMMONIUM POLYMER | ROHM GMBH (DE) | 1988-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360107-A1 | USE OF MAZINDOL TO TREAT NERVOUS SYSTEM DISORDERS | PNMT, COMT, MAOA | TET2 2777/4885FFAR3 1745/4885TET3 2030/4885 |
| US-20260014163-A1 | USE OF REBOXETINE TO TREAT FIBROMYALGIA | SLC6A4, SLC6A2, CRH | TET2 879/4885FFAR3 74/4885TET3 932/4885 |
| US-20260014142-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | CYP2D6, CYP3A43, OPRD1 | TET2 1208/4885FFAR3 340/4885TET3 1218/4885 |
| US-20030198673-A1 | Controlled release formulations coated with aqueous dispersions of acrylic polymers | ACR, PARG, AMPD1 | TET2 2063/4885FFAR3 278/4885TET3 2349/4885 |
| US-20260097040-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | HTR2B, HCRTR2, HTR1B | TET2 2763/4885FFAR3 746/4885TET3 2054/4885 |
| US-12616702-B2 | Use of reboxetine to treat narcolepsy | SLC6A4, SLC6A2, SLC18A2 | TET2 2193/4885FFAR3 1419/4885TET3 1856/4885 |
| US-20260137690-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | SLC6A4, SLC6A2, SLC6A11 | TET2 2059/4885FFAR3 264/4885TET3 1586/4885 |
| US-20260014165-A1 | USE OF ESREBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS SUCH AS FIBROMYALGIA | FAAH, HTR2B, HTR5A | TET2 3466/4885FFAR3 147/4885TET3 3456/4885 |
| US-12447155-B2 | Use of reboxetine to treat narcolepsy | HCRTR1, HCRTR2, AANAT | TET2 3436/4885FFAR3 711/4885TET3 2422/4885 |
| US-20260041691-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | SLC6A4, SLC6A2, MAPT | TET2 2163/4885FFAR3 521/4885TET3 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.